All News

Robert B Chao, MD Tweet
@Bweber04 on recurrent pericarditis especially some seen in our lupus population IL-1 inhibition with Rilonacept really redefining treatment success and altering the typical treatment algorithm @RheumNow #ACR23 https://t.co/Ey1DN8eSXT
Eric Dein Tweet
Later today at #ACR23 at 4pm See Ab#2545 on IV secukinumab for AxSpA Read about it now on @RheumNow: https://t.co/s9IinpVxgR
Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Mike Putman Tweet
EBRheum
Interesting counterpoint to a tweet from a few days ago re:black box warning for JAKs No change in utilization rates post black box... maybe people had already baked this into the cake by then? @RheumNow #ACR23 Abstr 2142 https://t.co/K9cWbRSWV6
Mike Putman Tweet
EBRheum
Amazing & thoughtful poster re:protocol violates in TICOSPA trial 51.2% of pts violated T2T protocol at least once... but did not impact primary outcome Good baseline for future "strategy" style pragmatic trials @RheumNow #ACR23 #ACRBest Abstr2201 https://t.co/FhctgFNdNP
Md Yuzaiful Md Yusof Tweet
#ACR23 Late-Breaking Abstr#L09 In a crowded market, you’ve got to stand out. Phase 2 RCT of LNK01001, a highly selective JAK1-i in China: improvement in ACR 20,50,70 vs PBO at WK12. Those in PBO who didn’t meet ACR20 improved after receiving Tx. Very low infections @RheumNow https://t.co/ZbJFNHOtFT
Eric Dein Tweet
A#L09 #ACR23 @RheumNow New JAK! LNK01001 Chinese pts with mod-severe RA, csDMARD failures 12mg/24mg/PBO: W12: ACR20 60/73/31%, ACR50 40/42/9, ACR70 12/21/2% Stat signif diff reached at wk 1 for ACR20! Improved DAS28, HAQ-DI Wk24 ext: 91% remain in ACR 20 AEs: HLD noted https://t.co/RXOMzxGOTy
Eric Dein Tweet
CV Events in AS by Rx A#L11 @RheumNow #ACR23 43K pts from Korean data Rates of incident MI or CV: 18.7 per 10,000 py in non-bDMARD pt 8.9 in TNF 12.9 in IL-17 TNFi reduced risk of CVD HR 0.7, not signif for IL-17 Supports idea of TNFi giving a cardioprotective effect? #ACRBest https://t.co/SvVVDSU23z
Eric Dein Tweet
ARTIC REWIND: To taper or not? A#L07 #ACR23 @RheumNow RA pts taper TNFi in stable remission No taper group: 85% flare free in 3 yrs Taper grp: only 25% Lower Boolean 2.0 Remission rates Don't taper off a good thing! https://t.co/KnJrEfVFkV
Janet Pope Tweet
Lessons for #CVD in #inflammatory #rheumatic #diseases #ACR23 @RheumNow @ACRheum #ACRbest -Negative #coronary #calcification doesn’t r/o presence of #microvascular #dysfunction - work w #cardiologist for@proper@imaging for #Dx -for #CAD or #pericarditis #Colchicine is GOOD https://t.co/dMO1FpoA2a
Janet Pope Tweet
Excellent session: Navigating CV risk for #inflammatory #arthritis - view from #cardiology #ACR23 14T118 @RheumNow @ACRheum https://t.co/WKhh0TonE8
Md Yuzaiful Md Yusof Tweet
#ACR23 Late-Breaking Abstr#L14 Which team are you on? IL5-i or IL5-receptor-i #EGPA. Phase 3 H2H RCT showed similar efficacy btw Mepolizumab and Benralizumab, with more pts fully tapering off GC at WK52 favouring BENRA. Rapid reduction in Eosinophils too @RheumNow #ACRBest https://t.co/cXhSS80mA2
Janet Pope Tweet
Is #cardiology now a specialty like #rheumatology with bDMARDs? Many pathways discussed for CVD in #rheumatoid #arthritis. And biologics for lowering lipids too! #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ 14T118. More overlap of pts over time! https://t.co/blv5GmHTGe
Eric Dein Tweet
A#L06 #ACR23 @RheumNow Refractory juv SSc 6m-2y after autolog Stem Cell Tx - 5 patients HAQ VAS improved 75% (48-99%) All: mRSS MCID by 6 mo, 87% aver improvement, sustained at 2y GI: GIT mean 55% improvement, 1 unchanged FVC stable, DLCO improv >10% in 2, 5-10% in 2 #ACRBest https://t.co/cc6YToVEO5
Janet Pope Tweet
#Cardiology imaging has advanced - work with #cardiologists to know what to order - esp for our Pts w #inflammatory #diseases #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ 14T118 https://t.co/RuHJuy7Dh2
Eric Dein Tweet
MANDARA: Benralizumab v Mepolizumab in EGPA A#L14 #ACR23 @RheumNow P3, 52w RCT, 140 pts Remission rate: 59% Ben, 56.5% Mep Relapse rate 30% in both 86% Ben, 74% Mep had reduction of GC dose 50%+, 41% v 26% tapered off SAEs: 6% Ben, 13% Mep Concl: Non-inferiority of Ben v Mep https://t.co/mSIFsDq8eL
Mike Putman Tweet
EBRheum
I continue to be underwhelmed by nintedanib, esp in RA-ILD Data from INBUILD-ON, f/u study to the INBUILD basket trial Persistent loss of FVC... wonder how pts would have done had they received an RA-active DMARD? Need H2H vs TNFs & real DMARDs @RheumNow #ACR23 Abstr 2158 https://t.co/56PgC6Uc67
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×